Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
James F. Casella, MD
Healthcare Provider Director of the Basic and Translational Research Program
Comprehensive Sickle Cell Center
and MD Hemophilia Treatment Center
The Johns Hopkins Hospital
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, Maryland, United States
Dr. James Casella is a professor of pediatrics and oncology at the Johns Hopkins University School of Medicine. As the Johns Hopkins’ Rainey Professor of Pediatric Hematology, Dr. Casella is chief of the Division of Pediatric Hematology at Johns Hopkins Children’s and director of the Basic and Translational Research Program in Sickle Cell Disease, Comprehensive Sickle Cell Center and the Maryland Hemophilia Treatment Center at Johns Hopkins.
He supervises several labs investigating the cellular and molecular basis of pediatric blood-borne diseases. He is seeking to develop better treatments for sickle cell disease and the prevention of central nervous system complications of this disorder, including stroke.
A research scientist as well as a clinician, he co-directs the hematology/oncology fellowship program at Johns Hopkins Hospital and is an adjunct senior investigator (Pediatric Oncology Branch) in the Division of Clinical Sciences, National Cancer Institute, National Institutes of Health. He is also director of the NHLBI-funded K12 in benign hematology program at Johns Hopkins that trains young clinician/investigators in benign hematology and transfusion medicine.
+myBinderRelated Content
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
Lewis Hsu, MD, PhDDr. Lewis Hsu is a pediatric hematologis...
-
Clayton Andrews, LAPCClayton Andrews is a 35-year-old patient...
-
Webinar Series: Sickle Cell Science: Path to Progress – Sickle Cell Disease Care in the Emergency Department: ...To commemorate Sickle Cell Awareness Mon...
-
Targeted hydroxyurea education after an emergency department visit increases hydroxyurea use in children with sickle...Objective: To evaluate the impact of an...
-
Acute Care Utilization Is More Common in Patients with Sickle Cell Disease Who Have Chronic Complications and Chroni...Background: We undertook a large multisi...
-
The Life, Death, and Dream of a Research Diversity Crusader“We want to have a nation in which the...
